May zoledronic acid have negative effects on cognition and muscle performance?

Abstract

Background

We aimed to investigate the effects of zoledronic acid treatment on daily living activities, cognitive functions, depression, muscle strength, and performance.

Methods

The study was conducted retrospectively. Bone mineral densitometry (BMD) values, Katz activities of daily living (ADL), Lawton-Brody instrumental activities of daily living (IADL), mini mental state examination (MMSE), geriatric depression scale (GDS), mini nutritional assessment (MNA), grip strength, and gait speed scores before and 6 months after zoledronic acid administration were compared.

Results

A total of 115 patients were included in the study. There was a significant increase in lumbar total (p < .001), femoral neck (p = .002), and femur total (p = .001) BMD values after zoledronic acid treatment. Significant decrease was found in MMSE (p = .016) and gait speed scores (p = .008) after zoledronic acid treatment, but no significant difference was found in terms of Katz ADL, Lawton-Brody IADL, MNA, GDS, and grip strength (p > .05).

Conclusion

Our study indicated that zoledronic acid did not affect daily living activities, depression, and muscle strength. Although we have concluded that cognitive and muscle performance may be adversely affected by zoledronic acid treatment.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Bhansali A (2012) Metabolic bone disease: newer perspectives. Indian J Endocrinol Metab 16(Suppl 2):S140–S141

    PubMed  PubMed Central  Google Scholar 

  2. 2.

    Maclaughlin EJ, Sleeper RB, McNatty D et al (2006) Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag 2(3):281–295

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Zadeh AF, Hanafi MG, Kiasat A, Mousavi M (2019) Evaluation of the tibial cortical thickness accuracy in osteoporosis diagnosis in comparison with dual energy X-ray absorptiometry. J Family Med Prim Care 8(2):523–527

    PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    U.S. Preventive Services Task Force (2011) Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 154(5):356–364

    Article  Google Scholar 

  5. 5.

    Lewiecki EM (2010) Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis 1(3):115–128

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Mottaghi P (2010) Intravenous bisphosphonates for postmenopausal osteoporosis. J Res Med Sci. 15(3):175–184

    CAS  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Pazianas M, Abrahamsen B, Ferrari S, Russell RG (2013) Eliminating the need for fasting with oral administration of bisphosphonates. Ther Clin Risk Manag 9:395–402

    PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Dalle Carbonare L, Zanatta M, Gasparetto A, Valenti MT (2010) Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosismanagement. Drug Healthc Patient Saf 2:121–137

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  9. 9.

    Dilek B, Şahin E, Erdem D, et al. (2017) Patient satisfaction, preference and side effects after annual zoledronic acid infusion in patients with osteoporosis 23(1): 21–25

  10. 10.

    Liu M, Guo L, Pei Y, Li N, Jin M, Ma L, Liu Y, Sun B, Li C (2015) Efficacy of zoledronic acid in treatment of osteoporosis in men and women-a meta-analysis. Int J Clin Exp Med 8(3):3855–3861

    CAS  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Wang C (2017) Efficacy and safety of zoledronic acid for treatment of postmenopausal osteoporosis: a meta-analysis of randomized controlled trials. Am J Ther 24(5):e544–e552

    PubMed  Article  Google Scholar 

  12. 12.

    Devogelaer JP, Brown JP, Burckhardt P, Meunier PJ, Goemaere S, Lippuner K, Body JJ, Samsioe G, Felsenberg D, Fashola T, Sanna L, Ortmann CE, Trechsel U, Krasnow J, Eriksen EF, Garnero P (2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18(9):1211–1218

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Hsieh PC (2016) Effectiveness and safety of zoledronic acid in the treatment of osteoporosis. Orthopedics. 39(2):e263–e270

    PubMed  Article  Google Scholar 

  14. 14.

    Kotian P, Boloor A, Sreenivasan S (2016) Study of adverse effect profile of parenteral zoledronic acid in female patients with osteoporosis. J Clin Diagn Res 10(1):OC04–OC06

    CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Wark JD, Bensen W, Recknor C, Ryabitseva O, Chiodo J, Mesenbrink P, de Villiers TJ (2012) Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int 23(2):503–512

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, HORIZON Recurrent Fracture Trial (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367(18):1714–1723

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Tasci I, Safer U, Cintosun U, Bozoglu E, Naharci I, Aydogdu A, Meric C, Doruk H (2016) Zoledronic acid use and risk of cognitive decline among elderly women and men with osteoporosis. Endocr Metab Immune Disord Drug Targets 16(1):32–38

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Gokosmanoglu F, Varim C, Atmaca A et al (2016) The effects of zoledronic acid treatment on depression and quality of life in women with postmenopausal osteoporosis: a clinical trial study. J Res Med Sci 21:112

    PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    Arik G, Varan HD, Yavuz BB, Karabulut E, Kara O, Kilic MK, Kizilarslanoglu MC, Sumer F, Kuyumcu ME, Yesil Y, Halil M, Cankurtaran M (2015) Validation of Katz index of independence in activities of daily living in Turkish older adults. Arch Gerontol Geriatr 61(3):344–350

    PubMed  Article  Google Scholar 

  21. 21.

    Hopkins RO, Suchyta MR, Kamdar BB, Darowski E, Jackson JC, Needham DM (2017) Instrumental activities of daily living after critical illness: a systematic review. Ann Am Thorac Soc 14(8):1332–1343

    PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Goudsmit M, van Campen J, Schilt T, Hinnen C, Franzen S, Schmand B (2018) One size does not fit all: comparative diagnostic accuracy of the rowland universal dementia assessment scale and the mini mental state examination in a memory clinic population with very low education. Dement Geriatr Cogn Dis Extra 8(2):290–305

    PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Durmaz B, Soysal P, Ellidokuz H, Isik AT (2018) Validity and reliability of geriatric depression scale-15 (short form) in Turkish older adults. North Clin Istanb 5(3):216–220

    PubMed  PubMed Central  Google Scholar 

  24. 24.

    Sarikaya D, Halil M, Kuyumcu ME, Kilic MK, Yesil Y, Kara O, Ozturk S, Gungor E, Karabulut E, Balam Yavuz B, Cankurtaran M, Ariogul S (2015) Mini nutritional assessment test long and short form are valid screening tools in Turkish older adults. Arch Gerontol Geriatr 61(1):56–60

    PubMed  Article  Google Scholar 

  25. 25.

    Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M, Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2, Bautmans I, Baeyens JP, Cesari M, Cherubini A, Kanis J, Maggio M, Martin F, Michel JP, Pitkala K, Reginster JY, Rizzoli R, Sánchez-Rodríguez D, Schols J (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16–31

    PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Satoh T, Kimura M, Matsumoto K, Tabata KI, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S (2009) Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer. 115(15):3468–3474

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Sunyecz JA (2010) Zoledronic acid infusion for prevention and treatment of osteoporosis. Int J Women's Health 2:353–360

    CAS  Article  Google Scholar 

  28. 28.

    Nasiruddin M, Fayazuddin M, Zahid M et al (2014) Acute delirium in an elderly woman following zoledronate administration. J Pharmacol Pharmacother 5(3):217–219

    PubMed  PubMed Central  Article  Google Scholar 

  29. 29.

    Safer U, Safer VB, Demir SO et al (2016) Effects of bisphosphonates and calcium plus vitamin-D supplements on cognitive function in postmenopausal osteoporosis§. Endocr Metab Immune Disord Drug Targets 16(1):56–60

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Tow A, Holtzer R, Wang C, Sharan A, Kim SJ, Gladstein A, Blum Y, Verghese J (2016) Cognitive reserve and postoperative delirium in older adults. J Am Geriatr Soc 64(6):1341–1346

    PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Zameer S, Najmi AK, Vohora D, Akhtar M (2018) Bisphosphonates: future perspective for neurological disorders. Pharmacol Rep 70(5):900–907

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Gong L, Altman RB, Klein TE (2011) Bisphosphonates pathway. Pharmacogenet Genomics 21(1):50–53

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Schultz BG, Patten DK, Berlau DJ (2018) The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl Neurodegener 7:5

    PubMed  PubMed Central  Article  Google Scholar 

  34. 34.

    Orth M, Bellosta S (2012) Cholesterol: its regulation and role in central nervous system disorders. Cholesterol. 2012:292598

    PubMed  PubMed Central  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Remzi Bahşi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bahşi, R., Atmiş, V., Turgut, T. et al. May zoledronic acid have negative effects on cognition and muscle performance?. Ir J Med Sci 189, 191–196 (2020). https://doi.org/10.1007/s11845-019-02086-5

Download citation

Keywords

  • Cognitive function
  • Gait speed
  • Zoledronic acid